Skip to main content
Premium Trial:

Request an Annual Quote

CombiMatrix Revenues Up in Q2, Losses Down

NEW YORK, July 23 (GenomeWeb News) - CombiMatrix Thursday reported $750,000 in revenues for the second quarter, up from $6,000 in the same quarter of last year.


Revenues were down significantly compared to the first quarter, when the company recorded $17.6 million in revenues, $17.3 million of which were deferred revenues under a 15-year microarray development contract with Roche the companies signed in 2001.


The company, a Mulkiteo, Wash., subsidiary of Acacia Research, recorded a net loss of $3.5 million, compared to $5.2 million in the same period of 2003.


R&D expenses were $2.1 million, compared to $2.2 million in the same period of 2003.


As of June 30, CombiMatrix had $28.9 million in cash, cash equivalents and short-term investments, compared to $17.3 million at the end of 2003. In April, Acacia Research raised $13.7 million in a stock sale of Acacia Research - CombiMatrix common stock, and attributed the proceeds to CombiMatrix.

The Scan

Not Immediately Told

The US National Institutes of Health tells lawmakers that one of its grantees did not immediately report that it had developed a more infectious coronavirus, Science says.

Seems Effective in Kids

The Associated Press reports that the Pfizer-BioNTech SARS-CoV-2 vaccine for children appears to be highly effective at preventing symptomatic disease.

Intelligence Warning on Bioeconomy Threats

US intelligence warns over China's focus on technologies and data related to the bioeconomy, the New York Times reports.

PLOS Papers on Campylobacteriosis Sources, Inherited Retinal Dystrophies, Liver Cancer Prognosis

In PLOS this week: approach to uncover source of Campylobacteriosis, genetic risk factors for inherited retinal dystrophies, and more.